Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injection solution for intravenous and subcutaneous use. It is employed to prevent and treat thromboembolic conditions such as deep vein thrombosis and pulmonary embolism in surgical, medical and dialysis patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures consistent quality and regulatory compliance for global distribution.

Innohep, a low molecular weight heparin, is used in several thromboembolic disease states to inhibit clot formation. - Prevention of deep vein thrombosis (DVT) in surgical patients: reduces postoperative clot incidence. - Treatment of acute deep vein thrombosis: facilitates clot resolution and prevents extension. - Prevention and treatment of pulmonary embolism: lowers risk of embolic events and aids recovery. - Prevention of clot formation during hemodialysis or other medical procedures: maintains circuit patency.

Tinzaparin sodium may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding (e.g., gum or nosebleeds): slight hemorrhage not requiring medical intervention. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk. - Major bleeding: gastrointestinal or intracranial hemorrhage requiring urgent care. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Severe allergic reaction: anaphylaxis or urticaria.

Before initiating Innohep, clinicians should evaluate several clinical factors to minimize risk. - Renal impairment: assess kidney function and consider dose adjustment or anti‑Xa monitoring. - Bleeding risk: review patient history for recent surgery, trauma or active hemorrhage. - Concomitant anticoagulants: avoid or closely monitor use with other blood thinners. - Pregnancy: use only when potential benefit outweighs potential fetal risk. - Surgery or invasive procedures: discontinue appropriately prior to the intervention. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep can interact with other medications that affect hemostasis or drug metabolism, requiring careful management.

Major Interactions (Avoid): - Concurrent unfractionated heparin: additive anticoagulant effect increases bleeding risk. - Combined therapy with warfarin without proper bridging: may cause over‑anticoagulation. - Use with potent antiplatelet agents (e.g., clopidogrel) in high‑risk patients: heightened hemorrhagic potential.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate bleeding tendencies. - Selective serotonin reuptake inhibitors (SSRIs): can impair platelet function and increase bleed risk. - Thrombolytic agents: additive effect on clot dissolution may lead to severe bleeding.